All In MedTech

Device Trial Radar · NCT07559188

Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Azalea VisionNot on our public-company list
Sponsor type
Industry
First posted
Apr 30, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the effectiveness of the NOA lens, a custom-made scleral contact lens developed by Azalea Vision BV, in improving visual quality for individuals with keratoconus and presbyopia. This clinical study investigates a new lens design featuring a specific central aperture (opening) intended to enhance image quality by increasing depth of focus and reducing optical aberrations. The NOA lens serves as a functional prototype for future "smart lens" technology, specifically the ALMA Smart Lens. The study aims to determine if this specialized lens provides a solution for patients whose visual needs are not fully met by conventional glasses or contact lenses. The investigation will compare a standard refractive scleral lens (Type 1) against the aperture-integrated lens (Type 2) to validate the "pinhole effect" in improving vision and reducing higher-order aberrations.

Conditions

  • Keratoconus
  • Presbyopia
  • Scleral Contact Lenses
  • Pinhole

Interventions

  • NOA lens type 1Device

    Provides standard refractive correction. It is a clear (un-printed) lens used only to design the type 2 lens by assessing on-eye centration and stability. It also acts as the reference standard for baseline assessments in the NOA study

  • NOA lens type 2Device

    Incorporates an integrated optical aperture (pinhole) created by an opaque dye, in addition to standard refractive correction. This opaque layer is printed on an internal surface and sealed within the lens cavity. The inclusion of this optical aperture is intended to enhance depth of focus (the "pinhole effect") and reduce the impact of optical aberrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mode of action NOA lens in keratoconus groupTime frame: As assessed at the final study visit 3 (=approximately 6 weeks after baseline) compared to the baseline visit 2 (=day 0 + approximately 6 weeks)
  2. Mode of action NOA lens in presbyopia groupTime frame: As assessed at the final study visit 3 (=approximately 6 weeks after baseline) compared to the baseline visit 2 (=day 0 + approximately 6 weeks)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University Hospital Antwerp (UZA)

    Antwerp, Belgium · Recruiting

  • Visser Contactlenzen Brunssum

    Brunssum, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.